A new monoclonal antibody, invasive group A strep, and genital herpes topped the list of this week's most-read stories.
In a new CDC report, these immunizations aid against emergency department and urgent care encounters in immunocompetent adults.
The Centers for Disease Control and Prevention (CDC) is looking into the possibility of this rare group of infections emerging.
Genital herpes (HSV-2) affects quality-of-life but also causes substantial economic losses, especially in low- and middle-income countries.
Virax Biolabs has developed a T-cell testing platform to develop an immune risk profile against viral threats.
Roche’s Actemra is the first FDA approved monoclonal antibody to be used for COVID-19.